CTL Analyzers LLC

CTL Analyzers LLC, doing business as Cellular Technology LTD, manufactures and sells immunology laboratory analyzers—principally IMMUNOSPOT and ELISPOT systems—and maintenance services to federal research agencies as a prime contractor on full-and-open purchase orders. The vendor is a small business based in Shaker Heights, Ohio, competing without set-aside designation on most awards, though Total Small Business set-asides appear on roughly 20% of its recent footprint.

CTL Analyzers operates exclusively as a prime contractor (111 awards, 100% of its footprint) and does not subcontract. Its capability portfolio centers on the procurement and installation of benchtop immunology analyzers used for immune-cell assays, reagent supply, and multi-year preventative maintenance agreements. Representative awards include a $67,775 firm fixed-price purchase order from the Food and Drug Administration in August 2024 for an IMMUNOSPOT analyzer to be delivered to Silver Spring, Maryland; a $97,425 order from the National Institute of Allergy and Infectious Diseases (NIAID) in September 2023 for a CTL IMMUNOSPOT S6 Universal M2 Analyzer and BIOSTACK1 system to support infectious-disease research in Beachwood, Ohio; a $69,850 Total Small Business set-aside from the Department of Agriculture Agricultural Research Service in June 2023 for an ELISPOT Imager at the National Animal Disease Center in Ames, Iowa; and a $58,950 FDA order in August 2022 for an IMMUNOSPOT S6 Macro M2 analyzer plus two option years of preventative maintenance.

Customer concentration is heavily skewed to Department of Health and Human Services agencies. The top five funding entities account for 65% of award count and 61% of combined potential value, led by CDC Pittsburgh (20 awards, $587 thousand combined potential value), NIAID (12 awards, $440 thousand), and Department of Agriculture Midwest Area (19 awards, $283 thousand). By dollar magnitude, the Department of the Army Medical Command ranks highest at $667 thousand across six awards, but CDC Pittsburgh and NIAID dominate the recurring relationship base. The vendor has worked with 22 distinct federal agencies, including the National Cancer Institute, Department of Veterans Affairs, and Department of Commerce, indicating broad penetration of federal research institutions.

Activity volume has contracted sharply. The vendor received seven awards in 2022 but only two in 2023, two in 2024, one in 2025, and one in 2026—a steep decline across the past four years. The combined potential value across all 111 awards is $3.8 million, with $3.7 million obligated (98% cash-out rate), indicating nearly complete execution of historical work. Only one award (combined potential value $24 thousand) completes in the next twenty-four months, signaling minimal near-term recompete exposure but also a dormant pipeline. NAICS concentration is tight: 83 of 111 awards (75%) fall under Analytical Laboratory Instrument Manufacturing, with the remainder split across equipment maintenance and repair categories.